Craig C.  Parker net worth and biography

Craig Parker Biography and Net Worth

CEO of Surrozen

Craig Parker brings more than 25 years of science and business experience across leadership positions in both public and privately-held biopharmaceutical companies, as well as within financial organizations. Most recently, he was Senior Vice President of Corporate Development at Jazz Pharmaceuticals. He previously served as Executive Vice President of Corporate Development and Scientific Affairs at Geron Corporation, as well as Senior Vice President of Strategy and Corporate Development at Human Genome Sciences until the company’s acquisition by GlaxoSmithKline. He began his career in various positions at financial institutions on Wall Street, where he was one of the top-ranked biotechnology research analysts. Mr. Parker serves as a member of the Scientific Advisory Board of Life Sciences Institute, University of Michigan, and chairs the institute’s Leadership Council. He is a member of the Board of Directors at InduPro, Inc., a private biotechnology company, a Venture Partner at The Column Group, and a member of the Board of Directors at Synthekine Inc., a private biotechnology company. Mr. Parker earned a bachelor’s degree in biological sciences from the University of Chicago, an M.B.A. from the University of Michigan and attended the Georgetown University School of Medicine.

What is Craig C. Parker's net worth?

The estimated net worth of Craig C. Parker is at least $564.95 thousand as of May 4th, 2026. Mr. Parker owns 16,553 shares of Surrozen stock worth more than $564,954 as of May 7th. This net worth evaluation does not reflect any other investments that Mr. Parker may own. Learn More about Craig C. Parker's net worth.

How do I contact Craig C. Parker?

The corporate mailing address for Mr. Parker and other Surrozen executives is 1 PALMER SQUARE SUITE 305, PRINCETON NJ, 08540. Surrozen can also be reached via phone at 650-489-9000 and via email at [email protected]. Learn More on Craig C. Parker's contact information.

Has Craig C. Parker been buying or selling shares of Surrozen?

Over the course of the past ninety days, Craig C. Parker has sold $150,784.92 in Surrozen stock. Most recently, Craig C. Parker sold 4,524 shares of the business's stock in a transaction on Monday, May 4th. The shares were sold at an average price of $33.33, for a transaction totalling $150,784.92. Following the completion of the sale, the chief executive officer now directly owns 16,553 shares of the company's stock, valued at $551,711.49. Learn More on Craig C. Parker's trading history.

Who are Surrozen's active insiders?

Surrozen's insider roster includes Tim Kutzkey (Director), Yang Li (VP), Craig Parker (CEO), and Charles Williams (COO). Learn More on Surrozen's active insiders.

Are insiders buying or selling shares of Surrozen?

During the last year, Surrozen insiders bought shares 28 times. They purchased a total of 1,033,505 shares worth more than $16,849,523.68. During the last year, insiders at the sold shares 5 times. They sold a total of 10,828 shares worth more than $324,770.60. The most recent insider tranaction occured on May, 4th when VP Yang Li sold 1,584 shares worth more than $52,794.72. Insiders at Surrozen own 31.7% of the company. Learn More about insider trades at Surrozen.

Information on this page was last updated on 5/4/2026.

Craig C. Parker Insider Trading History at Surrozen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/4/2026Sell4,524$33.33$150,784.9216,553View SEC Filing Icon  
See Full Table

Craig C. Parker Buying and Selling Activity at Surrozen

This chart shows Craig C Parker's buying and selling at Surrozen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Surrozen Company Overview

Surrozen logo
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
Read More

Today's Range

Now: $34.13
Low: $31.33
High: $34.40

50 Day Range

MA: $28.42
Low: $25.00
High: $34.13

2 Week Range

Now: $34.13
Low: $5.90
High: $35.00

Volume

136,332 shs

Average Volume

144,249 shs

Market Capitalization

$392.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59